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S330 Poster Session IItransplanted with sex-mismatch CD34+ and CD3+ cells. Only when
mice were transplanted with a very low CD3:CD34 cell ratio (0.1:1)
a mix chimerism of huCD45+ CD3+ (21611%) T cells, CD19+
(4469%) B cell, CD34+ cells (361%), CD33+ myeloid cells
(1461%) and CD14+ monocytes (661%) was observed. To investi-
gate whether a single T cell population could cause stem cell rejec-
tion, mice were transplanted with selected CD3+CD4+ or
CD3+CD8+ T cells and CD34+ cells at 1:1 ratio. Rejection was ob-
served in 100% of mice transplanted with human CD3+CD4+ cells.
CD4+ cells in marrow and spleen were mostly CD45RA+. Instead,
mice transplanted with human CD3+CD8+ cells showed a mixed
chimerism of T, B and myeloid cells both in marrow and spleen.
Spleen was larger in recipients of CD4+ than CD8+ cells (p 5
0.005). Finally, spleen cells obtained from mice transplanted with
CD4+ or CD8+ cells were tested in-vitro as responders against irra-
diated CD34+ cells in mixed leucocyte cultures. Controls included
CD4+ or CD8+ cells that were frozen at the time of transplant.
Spleen CD4+ cells and both CD4+ and CD8+ control cells prolifer-
ated after stimulation with CD34+ cells, whereas spleen CD8+ cells
were unresponsive in-vitro. These results show that alloreactive
CD4+ T cells serve an important role in stem cell rejection while
CD8+ T cells appear to facilitate immune tolerance. Our work
also supports the use of NSG mice to analyze the mechanisms of
stem cell rejection or graft failure.339
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In recent decades, several advances were made in the management
of patients (pts) who underwent allogeneic hematopoietic stem cell
transplantation (HSCT). Tools that could predict TRM, based on
pre HSCT characteristics and co-morbidities were always sought.
Some of these tools are the modified hematopoietic cell transplanta-
tion co-morbidity index (HCT-CI).Our aim was to apply the
modified HCT-CI and correlated it with overall survival (OS) and
non-relapsemortality (NRM).This analysis include patients who un-
derwent an allogeneic HSCT, for malignant and non malignant he-
matological diseases, after high or low dose conditioning regimens,
from related and unrelated donor, from 1993 to 2010. Each co-mor-
bidity was assigned an integer weight, and theHCT-CI score was the
sum of this integer weights. The patients were then assigned to one
of the risk groups 0, 1, 2 and 3 ormore. Kaplan-Meier was applied for
estimation of overall survival. NRMwas estimated by cumulative in-
cidence considering primary relapse disease as competing risk.457
pts were analyzed at the beginning. However, 331 (72.4%) were
evaluable, 126 (27.6%) were excluded when at least one parameter
was missing. 208 (63%) were male with a median age of 36.5 (5-
65) years, 249 (75%) pts received high dose (HD) conditioning
and 82 (25%) low dose (LD). HCT-CI in HD was: 127 (51%) score
0; 39 (16%) score 1; 19 (7%) 2 and 64 (26%) score $ 3; in LD 33
(40%) score 0; 14 (17%) score 1; 8 (10%) score 2 and 27 (33%) score
$ 3. The median follow up in HD was 22 months (0-201) and 9 (0-
203) in LD.The adjustedOS at 10 year forHD conditioning accord-
ing to the HCT-CI was 55% for score 0, 34% for score 1-2 & 34%
for score$ 3 and for LD conditioning was 58% for score 0, 53% for
score 1-2 & 15% for score $ 3 (p\ 0.0001). The NRM rate in the
HD cohort was 32% in the pts with a score 0, 42% for score 1-2
and 53% in the score $ 3. In the LD cohort, the NRM was 23%
in the pts with a score of 0; 35% for score 1-2 and 54% in the score
$ 3 (p 5 0.002). The adjusted OS for conditioning type in patients
with cardiac valve disease was associated to a lower OS (29% and
33% p 5 0.002) whereas mild hepatic involvement was just signifi-
cant in the HD cohort. The OS and NRM were worse for score $
3 either in HD and LD groups. The heart valve disease emerged
as a worse outcome in both conditioning type and mild hepatic in-
volvement only in HD group. The HCT-CI showed to be a valid
tool to predict outcome after allogeneic HSCT.340
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Background: Mantle cell lymphoma (MCL) commonly has an ag-
gressive course and short survival with conventional chemotherapy.
Allogeneic stem cell transplantation (allo-HSCT) is a potentially cu-
rative treatment for a subset of MCL patients.
Methods:We conducted a retrospective analysis including 41 con-
secutive MCL patients who underwent allo-HSCT. Patients with
the blastic variant of MCL; extensive marrow involvement; multiple
relapses after conventional chemotherapy; relapse after autologous
stem cell transplantation (ASCT); unable to collect stem cells to un-
dergo ASCT were considered eligible for allo-HSCT.
Patients:Median age was 54 years (range: 32-70). Median time from
diagnosis to transplant was 18 months (range: 5.4-118). Disease sta-
tus at allo-HSCT included CR1 (n 5 7), induction failure (n 5 13),
1st relapse (n5 13);.1st relapse (n5 8). 31 patients (76%) had stage
IV disease at diagnosis. Median number of prior regimens was 3
(range: 1-7). 35 patients (85%) had chemosensitive disease. 25
patients received allo-HSCT from a matched sibling and 16 from
unrelated donors. Conditioning regimens were fludarabine/melpha-
lan-based (n5 29), or TBI-based (n5 12). Most (80%) received pe-
ripheral blood stem cells. 23 (56%) received tacrolimus and
sirolimus; 18 received cyclosporine or tacrolimus with methotrexate
(n 5 12) or cellcept (n 5 6) for GVHD prophylaxis.
Results: At a median follow-up of 1.7 years, 59% of the patients
were still alive. The estimated 5-year overall and progression free-
survival was 51% (95% CI, 31% - 68%) and 30% (95% CI, 14% -
48%), respectively.The 5-year cumulative incidence of relapse and/
or progression was 43% (95% CI, 26% - 63%). The incidence of
acute and chronic GVHD was 56% and 63%, respectively. The
1-year and 5-year non-relapse related mortality (NRM) was 15 %
(95% CI, 7% - 29%) and 27% (95% CI, 15% - 43%). Factors asso-
ciatedwith increased risk of death and/or disease relapse/progression
were: time from diagnosis to transplant, advanced disease status at
transplant and prior ASCT.Patients transplanted after one or more
relapse events were at 7.28 times the risk of failure compared to those
in first CR1 (95%CI: 0.94 - 56.5; p 5 0.06).
Conclusions:These results suggest that long-term disease control is
possible after allo-HSCT for a subset of patients with MCLwith ac-
ceptable toxicity. Allo-SCT during CR1may offer long-term disease
control in patients with blastoid variant or those unable to undergo
autologous SCT.341
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Introduction: Transient elastography (TE) is a valuable non-inva-
sive method to assess liver fibrosis. The present study aimed to eval-
uate the diagnostic value of TE in the assessment of hepatic fibrosis
in patients with b-thalassemia major (TM) who are candidates for
hematopoietic stem cell transplantation.
Method:We prospectively assessed the results of TE in 41 b-thalas-
semia major patients (median age of 7 years; range 2.6-20 years;
65.9%male) who were candidates for hematopoietic stem cell trans-
plantation (HSCT) and compared these results with the histological
fibrosis stage from liver biopsies. The diagnostic values were com-
pared by calculating the area under the receiver operating character-
istic curves (AUROCs).
